Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316519 | 0.75 | RAB9A (0.41) | POLBNPC1RAB9AKMT2ACYP2C19 | |
| SCHEMBL698662 | 0.73 | NPC1 (0.46) | POLBNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL219809 | 0.71 | SMN1; SMN2 (0.41) | POLBNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1907972 | 0.71 | NPC1 (0.40) | POLBNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1904592 | 0.71 | ALDH1A1 (0.38) | POLBNPC1RAB9AMAPK14CYP2C19 | |
| SCHEMBL3392199 | 0.71 | POLB (0.36) | POLBNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1908196 | 0.71 | NR4A3 (0.41) | POLBNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5558900 | 0.69 | RAB9A (0.53) | NPC1RAB9AKMT2AMEN1CYP2C19 | |
| SCHEMBL1906824 | 0.69 | KEAP1 (0.43) | POLBNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL7040267 | 0.68 | MAPT (0.38) | POLBNPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373191-B1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-06-05 | — | — | EP | claimed |
| EP-1370530-B1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-29 | — | — | EP | claimed |
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-22 | — | — | US | claimed |
| US-7713963-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-11 | — | — | US | claimed |
| US-7709478-B2 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | claimed |
| EP-1362027-B1 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-05-21 | — | — | EP | claimed |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-12 | — | — | US | claimed |
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | claimed |
| US-20040225013-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-11 | — | — | US | claimed |
| US-6759412-B2 | FOR PRODUCING DRUGS USED FOR THERAPY OF CARDIOVASCULAR DISEASES, STABLE OR UNSTABLE ANGINA PECTORIS, CORONARY HEART DISEASE, PRINZMETAL ANGINA, ACUTE CORONARY SYNDROME, HEART FAILURE, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | claimed |
| EP-1373191-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | claimed |
| EP-1370530-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-12-17 | — | — | EP | claimed |
| EP-1362027-A2 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-11-19 | — | — | EP | claimed |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | claimed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | claimed |
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-09 | — | — | US | claimed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064546-A2 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064565-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | claimed |
| EP-2198861-B1 | eNOS transcription enhancers for use in the cell therapy of limb ischemia | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-06-25 | — | — | EP | disclosed |
| EP-1373191-B1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-06-05 | — | — | EP | disclosed |
| US-8309608-B2 | Endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells; for treating cardiomyopathy, congestive heart failure | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8163751-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| EP-1534277-B1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-09-14 | — | — | EP | disclosed |
| EP-1370530-B1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2198861-A2 | eNOS transcription enhancers for use in the cell therapy of ischemic heart diseases | Sanofi-Aventis Deutschland GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| US-7713963-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7709478-B2 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1682111-B1 | ENOS TRANSCRIPTION ENHANCERS FOR USE IN THE CELL THERAPY OF ISCHEMIC HEART DISEASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-01-06 | — | — | EP | disclosed |
| EP-1362027-B1 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-05-21 | — | — | EP | disclosed |
| US-7338956-B2 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-04 | — | — | US | disclosed |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-7186735-B2 | Acylated arylcycloalkylamines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-06 | — | — | US | disclosed |
| US-7179839-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| US-7105513-B2 | Cardiovascular disorders; strokes; hypotensive agents | SANOFI-AVERTIS DEUTSCHLAND GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1682111-A1 | ENOS TRANSCRIPTION ENHANCERS FOR USE IN THE CELL THERAPY OF ISCHEMIC HEART DISEASES | Sanofi-Aventis Deutschland GmbH (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1534277-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534275-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005044249-A1 | ENOS TRANSCRIPTION ENHANCERS FOR USE IN THE CELL THERAPY OF ISCHEMIC HEART DISEASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101599-A1 | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| EP-1529525-A1 | ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| EP-1529031-A1 | ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040225013-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6759412-B2 | FOR PRODUCING DRUGS USED FOR THERAPY OF CARDIOVASCULAR DISEASES, STABLE OR UNSTABLE ANGINA PECTORIS, CORONARY HEART DISEASE, PRINZMETAL ANGINA, ACUTE CORONARY SYNDROME, HEART FAILURE, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| US-20040082628-A1 | Acylated arylcycloalkylamines and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| WO-2004014369-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014842-A1 | ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014372-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1388341-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
| EP-1388535-A1 | Acylated arylcycloalkylamines and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
| EP-1388342-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
| EP-1373191-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| EP-1370530-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1362027-A2 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-09 | — | — | US | disclosed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064565-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064546-A2 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | EDNRA, LIPG, CYP11B1 | POLB 2752/4885NPC1 1665/4885RAB9A 3101/4885 |
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | LIPG, AADAC, AANAT | POLB 1575/4885NPC1 646/4885RAB9A 4422/4885 |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | POLB 3488/4885NPC1 425/4885RAB9A 2507/4885 |
| US-20040082628-A1 | Acylated arylcycloalkylamines and their use as pharmaceuticals | LIPG, AADAC, NAT1 | POLB 3039/4885NPC1 628/4885RAB9A 3810/4885 |
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | VEGFA, NR1H2, EDNRA | POLB 2962/4885NPC1 498/4885RAB9A 1984/4885 |
| US-20040225013-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | VEGFA, NR1H2, EDNRA | POLB 2962/4885NPC1 498/4885RAB9A 1984/4885 |
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | POLB 2961/4885NPC1 633/4885RAB9A 2472/4885 |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | EDNRA, VEGFA, EDNRB | POLB 2919/4885NPC1 355/4885RAB9A 2476/4885 |
| US-20050101599-A1 | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases | TNNI3, RUNX1, TNNT2 | POLB 418/4885NPC1 2181/4885RAB9A 3825/4885 |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | POLB 2932/4885NPC1 611/4885RAB9A 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.